The 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, which took place May 31–June 4 in Chicago, drew more than 32,000 oncology specialists from around the world.
A same-day biopsy program for women helped reduce disparities related to age, race, and insurance type in breast cancer care.
Researchers tested the MET inhibitor capmatinib in patients with non–small-cell lung cancer and a MET exon 14 skipping mutation.
Lurbinectedin may represent a new treatment option as second-line therapy for patients with small-cell lung cancer.
Cancer Network spoke with Anna Pavlick, MD, of NYU Langone Health, on the results of a phase II study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared with Montanide.
Cancer Network spoke with Adi Diab, MD, of MD Anderson Cancer Center, on the link between baseline tumor immune signatures and response to bempegaldesleukin and nivolumab in patients with advanced solid tumors.
Findings on the efficacy of the RET inhibitor BLU-667 in RET-altered medullary thyroid cancer and papillary thyroid cancer patients was presented at ASCO 2019.
Cancer Network spoke with Hussein Tawbi, MD, PhD, of MD Anderson Cancer Center, about the efficacy and safety of the combination of nivolumab plus ipilimumab in patients with symptomatic melanoma brain metastases.
Cancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan Kettering Cancer Center, about pursuing adjuvant immunotherapy for patients with melanoma.
An analysis of the ARAMIS trial looked at quality of life and other outcomes with darolutamide in men with nonmetastatic castration-resistant prostate cancer.